No Data
No Data
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Express News | Incyte To Present Late-Breaking Tafasitamab Data In Follicular Lymphoma At ASH 2024 Alongside 20 Oncology Portfolio Updates, Including Phase 3 InMIND Results And Virtual Analyst Event On December 12
S&P 500, Dow Hit Records Right After Open | Live Stock
TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Raises Target Price to $86
TD Cowen Remains a Buy on Incyte (INCY)
TD Cowen Adjusts Price Target on Incyte to $86 From $80, Keeps Buy Rating
No Data
No Data